GCP
KYTX icon

GSA Capital Partners’s Kyverna Therapeutics KYTX Stock Holding History

GSA Capital Partners’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,161
Closed -$139K – 2236
2026
Q1 		$139K Buy
+16,161
New +$135K 0.01% 1523

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

GSA Capital Partners's KYTX Position: Q2 2026 in Review

GSA Capital Partners sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 16,161 shares — an estimated $139K sold.

GSA Capital Partners first reported a position in KYTX in Q1 2026 and held it in 1 quarter. The position peaked at $139K in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • GSA Capital Partners reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 16,161 Kyverna Therapeutics shares in Q2 2026, an estimated $139K.
  • GSA Capital Partners first reported a position in Kyverna Therapeutics in Q1 2026 and held it in 1 quarter.
  • GSA Capital Partners's Kyverna Therapeutics position peaked at $139K in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.